Menu
Pipeline
PROGRAM
INDICATIONS
DISCOVERY
PRE-CLINICAL
PHASE 1/2
PIVOTAL
CAR-T (Allogeneic)
Memory NK (Allogeneic)
AML
AML = Acute Myeloid Leukemia
T-ALL = T-cell Acute Lymphoblastic Leukemia
LBL = Lymphoblastic Lymphoma
mAb = Monoclonal Antibody
Co-development of Wugen products in China, Hong Kong, Taiwan, Macao, and Singapore
Lead Programs
WU-NK-101
Super-Charged to attack cancer
- Opportunity to treat a wide variety of hematologic malignancies and solid tumors
- Better target killing through increases in cytokine production
- Enhanced ADCC for more robust response to antibody triggering
- Improved balance of KIR activating and inhibitory signals
- A Phase 1/2 clinical trial of WU-NK-101 (1:1) showed the therapy was well-tolerated, persistent, and active against AML
WU-CART-007
Engineered to target T-cell cancers
- Opportunity to treat T-ALL, an orphan disease that is most common in children and young adults
- Deletion of the target in CAR-T prevents CAR-T Vs. CAR-T killing (friendly-fire)
- Disruption of the T-cell receptor enables the use of allogeneic donor T cells with reduced risk of Graft Vs. Host Disease
- Use of allogeneic donors prevents malignant cell contamination
- Clinical trials testing the safety and efficacy of WU-CART-007 are actively enrolling patients
Next in our story
Next in our story
Copyright © 2024 Wugen. All Rights Reserved.
a COGNEO design